1stOncology™: Cancer Intelligence Service – Page 14672 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Advaxis to Host Business Update Conference Call on November 2, 2018

On October 26, 2018 Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, reported that the Company will host a business update call on Friday, November 2, 2018 (Press release, Advaxis, OCT 26, 2018, View Source [SID1234530210]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Advaxis’ senior management will host a conference call to provide a business update and pipeline discussion. The conference call and live audio webcast will begin at 11:00 a.m. Eastern time on Friday, November 2, 2018.

Conference Call & Webcast Information
WHEN: Friday, November 2, 2018 at 11:00 a.m. Eastern time
DOMESTIC DIAL-IN: (844) 348-6133
INTERNATIONAL DIAL-IN: (631) 485-4564
CONFERENCE ID: 1538717
WEBCAST: ir.advaxis.com/events-presentations

For those unable to participate in the live conference call or webcast, a digital recording will be available beginning November 2, 2018 two hours after the close of the conference call. To access the recording, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and provide the operator with the conference ID: 1538717. In addition, an audio webcast will be archived on the Company’s website for a period of time at www.advaxis.com.

Immunomic Therapeutics Senior Director of Corporate Development to Present at Precision Lung Cancer World R&D Summit

On October 26, 2018 Senior Director of Corporate Development at Immunomic Therapeutics Inc. Sia Anagnostou will speak at the Precision Lung Cancer World R&D Summit in Boston (Press release, Immunomic Therapeutics, OCT 26, 2018, View Source [SID1234530209]). Anagnostou’s presentation, titled "UNITE Technology as Nucleic Acid & Cell Based Immunotherapy: TERT – LAMP Case Study," will highlight Immunomic’s investigational UNiversal Intracellular Targeted Expression (UNITE) platform and its application in immuno-oncology. Immunomic’s technology platform has the potential to utilize the body’s natural biochemistry to develop a broad immune response, including antibody production, cytokine release and critical immunological memory, a method that could put UNITE at the crossroads of immunotherapies in a number of illnesses, including cancer. The investigational UNITE technology is currently being applied as a cancer immunotherapy in a Phase II clinical trial targeting glioblastoma multiforme (GBM). Anagnostou’s presentation will explore the broader potential of UNITE through discussion of the LAMP-based immunotherapy technology, AST-VAC2 (VAC2). VAC2 is an allogeneic cancer immunotherapy being developed by Asterias Biotherapeutics, Inc. in collaboration with Cancer Research UK and is currently in a Phase 1 clinical trial for treatment of non-small cell lung cancer.

Who: Sia Anagnostou, Senior Director of Corporate Development at Immunomic Therapeutics, Inc.

What: Presentation on Activating Immune Responses in Cancer

When: Monday, October 29 at 4:00 p.m. EDT

Where: Wyndam Boston Beacon Hill, 5 Blossom St., Boston, MA 02114

About UNITE

ITI’s investigational UNITE platform, or UNiversal Intracellular Targeted Expression, is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in humans. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.

Allergan Declares Fourth Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share

On October 26, 2018 Allergan plc (NYSE: AGN) reported that its Board of Directors has declared a cash dividend of $0.72 per ordinary share for the fourth quarter of 2018 (Press release, Allergan, OCT 26, 2018, View Source [SID1234530200]). The dividend will be paid on December 14, 2018 to shareholders of record at the close of business on November 13, 2018

Zepsyre® receives positive recommendation of the IDMC to continue with the Phase III trial in small-cell lung cancer (ATLANTIS)

On October 26, 2018 PharmaMar (MSE:PHM) has reported that the Phase III ATLANTIS trial has received from the Independent Data Monitoring Committee (IDMC) its recommendation that the trial, currently under way with Zepsyre (lurbinectedin, PM1183) in combination with doxorubicin in relapsed small-cell lung cancer patients should continue without any changes. This is the fourth IDMC safety data review that has been passed.

The IDMC’s recommendation came after having reached the targeted number of 600 patients recruited.

The ATLANTIS trial compares Lurbinectedin plus doxorubicin to physician’s choice of either Topotecan or CAV (cyclophosphamide, adriamycin, vincristine) in a 1 to 1 randomization. The primary endpoint is overall survival, and based on the expected number of events, the results are expected around the end of 2019. The trial is 90% powered to deliver a hazard ratio of 0.75.

Legal warning
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

Equity Placing to raise US$1,500,000

On October 26, 2018 Tiziana Life Sciences plc (AIM: TILS), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, reported that it has raised US$1,500,000 by the issue of 1,515,150 new ordinary shares ("Placing Shares") at a price of US$0.99 (75p) per share at a fixed exchange rate of GBP 1 : US$ 1.32 (the "Placing") (Press release, Tiziana Life Sciences, OCT 26, 2018, View Source [SID1234530137]).

Application will be made to London Stock Exchange plc to admit the Placing Shares to trading on AIM ("Admission") with Admission expected to occur on or around 19 November 2018. The Placing Shares will rank pari passu with the existing ordinary shares of nominal value 3 pence each in the capital of the Company (the "Ordinary Shares").

Following Admission, the fully diluted issued share capital of the Company will consist of 151,790,735 Ordinary Shares (assuming all options and warrants, vested and unvested, exercised and exercisable, were converted).

Total Voting Rights

In conformity with DTR 5.6.1, the Company notifies that as at the date of this announcement, it has a single class of shares in issue being Ordinary Shares and that following the issue of the Placing Shares, the total number of Ordinary Shares in issue will be 128,442,449. There are no Ordinary Shares held in treasury. Each Ordinary Share entitles the holder to a single vote at general meetings of the Company.

The figure of 128,442,449 Ordinary Shares may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.

The person who arranged for release of this announcement on behalf of the Company was Tiziano Lazzaretti, Chief Financial Officer of Tiziana.